These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 2860656)

  • 1. Clinical activity of GABA agonists in neuroleptic- and L-dopa-induced dyskinesia.
    Morselli PL; Fournier V; Bossi L; Musch B
    Psychopharmacology Suppl; 1985; 2():128-36. PubMed ID: 2860656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic response to progabide in neuroleptic- and L-dopa-induced dyskinesias.
    Ziegler M; Fournier V; Bathien N; Morselli PL; Rondot P
    Clin Neuropharmacol; 1987 Jun; 10(3):238-46. PubMed ID: 2900682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction and reversal of dopamine dyskinesia in rat, cat, and monkey.
    Lloyd KG; Willigens MT; Goldstein M
    Psychopharmacology Suppl; 1985; 2():200-10. PubMed ID: 2987905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Alabed S; Latifeh Y; Mohammad HA; Rifai A
    Cochrane Database Syst Rev; 2011 Apr; (4):CD000203. PubMed ID: 21491376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2001; (2):CD000203. PubMed ID: 11405955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares K; Rathbone J; Deeks J
    Cochrane Database Syst Rev; 2004 Oct; (4):CD000203. PubMed ID: 15494993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia.
    Soares KV; McGrath JJ; Deeks JJ
    Cochrane Database Syst Rev; 2000; (2):CD000203. PubMed ID: 10796320
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Movement disorders in patients with coexistent neuroleptic-induced tremor and tardive dyskinesia: EMG and pharmacological study.
    Rondot P; Bathien N
    Adv Neurol; 1987; 45():361-6. PubMed ID: 2881446
    [No Abstract]   [Full Text] [Related]  

  • 9. Pharmacology of the GABAergic system: effects of progabide, a GABA receptor agonist.
    Bartholini G
    Psychoneuroendocrinology; 1984; 9(2):135-40. PubMed ID: 6089242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Electrophysiological and pharmacological analysis of L-dopa-induced dyskinesia and tardive dyskinesia (author's transl)].
    Bathien N; Rondot P; Koutlidis RM
    J Physiol (Paris); 1981 Apr; 77(1):131-41. PubMed ID: 6112268
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats.
    Kaneda H; Shirakawa O; Dale J; Goodman L; Bachus SE; Tamminga CA
    Eur J Pharmacol; 1992 Feb; 212(1):43-9. PubMed ID: 1555638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dyskinesia: L-dopa-induced and tardive dyskinesia.
    Rascol O; Fabre N
    Clin Neuropharmacol; 2001; 24(6):313-23. PubMed ID: 11801806
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dopamine, GABA, cholecystokinin and opioids in neuroleptic-induced tardive dyskinesia.
    Ebadi M; Hama Y
    Neurosci Biobehav Rev; 1988; 12(3-4):179-87. PubMed ID: 2906420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of tetrahydroisoxazolopyridinol (THIP) in tardive dyskinesia: a new gamma-aminobutyric acid agonist.
    Korsgaard S; Casey DE; Gerlach J; Hetmar O; Kaldan B; Mikkelsen LB
    Arch Gen Psychiatry; 1982 Sep; 39(9):1017-21. PubMed ID: 6126170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological and therapeutic actions of GABA receptor agonists.
    Zivkovic B; Scatton B; Worms P; Lloyd KG; Bartholini G
    J Neural Transm Suppl; 1983; 18():319-26. PubMed ID: 6308150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic strategies against tardive dyskinesia. Two decades of experience.
    Jeste DV; Wyatt RJ
    Arch Gen Psychiatry; 1982 Jul; 39(7):803-16. PubMed ID: 6131655
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain gamma-aminobutyric acid abnormality in tardive dyskinesia. Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment.
    Thaker GK; Tamminga CA; Alphs LD; Lafferman J; Ferraro TN; Hare TA
    Arch Gen Psychiatry; 1987 Jun; 44(6):522-9. PubMed ID: 3034188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement in tardive dyskinesia after muscimol therapy.
    Tamminga CA; Crayton JW; Chase TN
    Arch Gen Psychiatry; 1979 May; 36(5):595-8. PubMed ID: 35117
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.